Vinflunine

Drugs

Volumn 70, Issue 10, 2010, Pages 1283-1293

  Frampton, James E ^a   Moen, Marit D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Bladder cancer; General; Research and development; Vinflunine

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IXABEPILONE; KETOCONAZOLE; NAVELBINE; PACLITAXEL; PEMETREXED; VINBLASTINE; VINCRISTINE; VINFLUNINE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; IC 50; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PLEURA MESOTHELIOMA; POPULATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RECIPIENT; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROTHELIUM; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; DRUG EFFECTS; DRUG RESISTANCE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; URINARY BLADDER NEOPLASMS;

MURINAE; VINCA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, TRANSITIONAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 77953847340     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204970-000000000-00000     Document Type: Review

References (44)

1. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-825
2. Agarwal N, Hussain M. Management of bladder cancer: current and emerging strategies. Drugs 2009; 69 (9): 1173-1187
3. Bellmunt J, Albiol S, Suarez C, et al. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2009; 69 (3): 211-222
4. Stenzl A, Cowan NC, De Santis M, et al. European Asso-ciation of Urology guidelines on bladder cancer: muscle-invasive and metastatic [online]. Available from URL: http://www.uroweb.org [Accessed 2010 May 28]
5. Bellmunt J, Albiol S, Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl. 4: iv79-80
6. Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr Opin Urol 2009 Sep; 19 (5): 533-539
7. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced blad-der cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008; 113: 1284-1293
8. Kruczynski A, Hill BT. Vinflunine, the latest vinca alkaloid in clinical development: a review of its preclinical anti-cancer properties. Crit Rev Oncol Hematol 2001 Nov; 40 (2): 159-173
9. Bellmunt J, Delgado FM, George C. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol 2008 Jun; 35 (3 Suppl. 3): S34-43
10. Lobert S, Ingram JW, Hill BT, et al. A comparison of ther-modynamic parameters for vinorelbine-and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998; 53: 908-915
11. Jordan MA. Mechanism of action of antitumour drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002 Jan; 2 (1): 1-17
12. Margolis RL, Wilson L. Microtubule treadmills: possible molecular machinery. Nature 1981 Oct 29; 293: 705-711
13. Ngan VK, Bellman K, Hill BT, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisyn-thetic vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001; 60: 225-232
14. Okouneva T, Hill BT, Wilson L, et al. The effects of vin-flunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003 Mar; 2: 427-436
15. Ngan NK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on micro-tubules. Cancer Res 2000 Sep 15; 60: 5045-5051
16. Fahy J, Hellier P, Breillout F, et al. Vinflunine: discovery and synthesis of a novel microtubule inhibitor. Semin Oncol 2008; 35 (3 Suppl. 3): S3-5
17. Kruczynski A, Barret JM, Etievant C, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluori-nated vinca alkaloid. Biochem Pharmacol 1998 Mar 1; 55 (5): 635-648
18. Jordan MA, Horwitz SB, Lobert S, et al. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol 2008 Jun; 35 (3 Suppl. 3): S6-12
19. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol 1998; 41 (6): 437-447
20. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo ex-perimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999 Mar; 35 (3): 512-520
21. Bonfil RD, Russo DM, Binda MM, et al. Higher antitumor activity of vinflunine than vinorelbine against an ortho-topic murine model of transitional cell carcinoma of the bladder. Urol Oncol 2002 Jul; 7 (4): 159-166
22. Kruczynski A, Poli M, Dossi R, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vin-flunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006 Nov; 42 (16): 2821-2832
23. Pourroy B, Honore S, Pasquier E, et al. Antiangiogenic concentrations of vinflunine increase the interphase micro-tubule dynamics and decrease the motility of endothelial cells. Cancer Res 2006 Mar 15; 66 (6): 3256-3263
24. Honore S, Pagano A, Gauthier G, et al. Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther 2008 Jul; 7 (7): 2080-2089
25. Simoens C, Vermorken JB, Korst AE, et al. Cell cycle effects of vinflunine, the most recent promising vinca alkaloid, and its interaction with radiation, in vitro. Cancer Che-mother Pharmacol 2006 Aug; 58 (2): 210-218
26. Simoens C, Lardon F, Pauwels B, et al. Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 2008 Feb 29; 8: 65
27. Etievant C, Barrett JM, Kruczynski A, et al. Vinflunine (20,20-difluoro-3,4-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998; 16 (1): 3-17
28. Kavallaris M, Annereau JP, Barret JM. Potential mechan-isms of resistance to microtubule inhibitors. Semin Oncol 2008 Jun; 35 (3 Suppl. 3): S22-7
29. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003 Apr; 14 (4): 630-637
30. Johnson P, Geldart T, Fumoleau P, et al. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 2006 May; 24 (3): 223-231
31. Mukohara T, Minami H, Nagai S, et al. Phase I study of i.v. vinflunine, a novel microtubule inhibitor, given every three weeks in Japanese patients with solid tumors [abstract no. 228]. 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego (CA), 53
32. Paule B, Saliba F, Gil-Delgado M, et al. Phase I and phar-macokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): pharmacokinetic results [abstract no. 2423]. J Clin Oncol 2007; 15 (18S): 102S
33. Lobert S, Puozzo C. Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol 2008 Jun; 35 (3 Suppl. 3): S28-33
34. Javlor 25 mg/ml concentrate for solution for infusion. Sum-mary of product characteristics. Boulogne: Pierre Fabre Medicament, 2009 35. Zhao X-P, Liu X-Q, Wang Y-S, et al. Pharmacokinetics, tissue distribution and excretion of vinflunine. Eur J Drug Metab Pharmacokinet 2006; 31 (2): 59-64
35. US National Library of Medicine and the National Institutes of Health. Glomerular filtration rate [online]. Available from URL:
36. Sheehan LI, Shen Y, Zyry B, et al. Effects of ketoconazole on the pharmacokinetics of intravenous vinflunine in subjects with advanced cancer [abstract no. 5444]. American Association for Cancer Research 100th Annual Meeting 2009; 2009 Apr 18-22; Denver (CO)
37. Zhao XP, Zhong J, Liu XQ, et al. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin 2007 Jan; 28 (1): 118-124
38. Sanoff HK, Davies J, Walko C, et al. Phase I trial of vin-flunine and pemetrexed in refractory solid tumors. Invest New Drugs 2009 Oct 15
39. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006 May 22; 94 (10): 1395-1401
40. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or me-tastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009 Sep 15; 115 (18): 4110-4117
41. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009 Sep 20; 27 (27): 4454-4461
42. Culine S, Lucas C, Salhi Y, et al. Updated survival results of the phase III trial comparing vinflunine (V) to best supportive care (BSC) in advanced transitional cell carcinoma of the urothelium (TCCU) after failure of a prior platinum-containing regimen. 25th Annual European Association of Urology Congress; 2010 Apr 16-20; Barcelona
43. European Medicines Agency. CHMP assessment report for Javlor (international nonproprietary name: vinflunine ditartrate) [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/javlor/H-983-en6.pdf [Accessed 2010 Mar 25]
44. European Medicines Agency. Committee for medicinal products for human use: summary of positive opinion for Javlor [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/opinion/Javlor-37089509en.pdf [Accessed 2010 Jan 7]